Entity Details

Primary name TPH2_HUMAN
Entity type UniProt
Source Source Link

Details

AccessionQ8IWU9
EntryNameTPH2_HUMAN
FullNameTryptophan 5-hydroxylase 2
TaxID9606
Evidenceevidence at protein level
Length490
SequenceStatuscomplete
DateCreated2003-05-09
DateModified2021-06-02

Ontological Relatives

GenesTPH2

GO terms

Show/Hide Table
GOName
GO:0004510 tryptophan 5-monooxygenase activity
GO:0005506 iron ion binding
GO:0005829 cytosol
GO:0007623 circadian rhythm
GO:0009072 aromatic amino acid family metabolic process
GO:0014823 response to activity
GO:0031667 response to nutrient levels
GO:0042427 serotonin biosynthetic process
GO:0043005 neuron projection
GO:0043627 response to estrogen
GO:0046219 indolalkylamine biosynthetic process
GO:0051384 response to glucocorticoid
GO:0051592 response to calcium ion
GO:0071285 cellular response to lithium ion

Subcellular Location

Show/Hide Table

Domains

Show/Hide Table
DomainNameCategoryType
IPR001273 Aromatic amino acid hydroxylaseFamilyFamily
IPR002912 ACT domainDomainDomain
IPR005963 Tryptophan 5-monooxygenaseFamilyFamily
IPR018301 Aromatic amino acid hydroxylase, iron/copper binding siteSiteBinding site
IPR019773 Tyrosine 3-monooxygenase-likeFamilyFamily
IPR019774 Aromatic amino acid hydroxylase, C-terminalDomainDomain
IPR036329 Aromatic amino acid monoxygenase, C-terminal domain superfamilyFamilyHomologous superfamily
IPR036951 Aromatic amino acid hydroxylase superfamilyFamilyHomologous superfamily
IPR041904 Tryptophan 5-hydroxylase, catalytic domainDomainDomain

Diseases

Show/Hide Table
Disease IDSourceNameDescription
608516 OMIMMajor depressive disorder (MDD)A common psychiatric disorder. It is a complex trait characterized by one or more major depressive episodes without a history of manic, mixed, or hypomanic episodes. A major depressive episode is characterized by at least 2 weeks during which there is a new onset or clear worsening of either depressed mood or loss of interest or pleasure in nearly all activities. Four additional symptoms must also be present including changes in appetite, weight, sleep, and psychomotor activity; decreased energy; feelings of worthlessness or guilt; difficulty thinking, concentrating, or making decisions; or recurrent thoughts of death or suicidal ideation, plans, or attempts. The episode must be accompanied by distress or impairment in social, occupational, or other important areas of functioning. Disease susceptibility is associated with variants affecting the gene represented in this entry.
613003 OMIMAttention deficit-hyperactivity disorder 7 (ADHD7)A neurobehavioral developmental disorder primarily characterized by the coexistence of attentional problems and hyperactivity, with each behavior occurring infrequently alone. Disease susceptibility is associated with variants affecting the gene represented in this entry. Naturally occurring variants of TPH2 with impaired enzyme activity could cause deficiency of serotonin production and result in an increased risk of developing behavioral disorders.

Drugs

Show/Hide Table
DrugNameSourceType
DB00150 TryptophanDrugbanksmall molecule
DB12095 Telotristat ethylDrugbanksmall molecule

Interactions

1 interaction

InteractorPartnerSourcesPublicationsLink
TPH2_HUMAN1433E_HUMANMINT17973628 details